METTL26

Across TCGA pan-cancer cohorts, METTL26 RNA differs between tumor and matched normal tissue in 17 of 18 cancer types tested, making tumor–normal expression one of METTL26’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where METTL26 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types METTL26 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

KIRC, COAD, and HNSC are the cancer types where METTL26 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in METTL26 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+1.641	<.001	12	view →
COAD	Female	II,III,IV	+1.698	<.001	11	view →
HNSC	Male	III,IV	+1.172	<.001	11	view →
KIRP	Male	III,IV	+0.878	<.001	9	view →
LIHC	Female	All	+0.878	<.001	8	view →
STAD	All	II,III,IV	+0.791	<.001	8	view →
BLCA	All	All	+0.568	<.001	8	view →
LUSC	All	II,III,IV	+0.574	<.001	7	view →
BRCA	All	III,IV	+0.941	<.001	6	view →
LUAD	Female	III,IV	+0.868	<.001	6	view →
KICH	Female	II,III,IV	−0.788	<.001	6	view →
CHOL	All	All	+1.503	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 17 lineages.

METTL26–KIRC

Open the KIRC breakdown →